DCSZ-11

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameDCSZ-11
Drug Alias NameDCSZ-11
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Complement component C1q receptor
TargetsComplement component C1q receptor
Therapy Area/IndicationsSolid tumoursRectal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDynamiCure Biotechnology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDynamiCure Biotechnology LtdWest China Hospital Of Sichuan University
Inactive CompaniesN/A
Active IndicationsSolid tumoursRectal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A